160 related articles for article (PubMed ID: 33441781)
1. Beta-blockers have no impact on survival in pancreatic ductal adenocarcinoma prior to cancer diagnosis.
Yang A; Zylberberg HM; Rustgi SD; Amin SP; Bar-Mashiah A; Boffetta P; Lucas AL
Sci Rep; 2021 Jan; 11(1):1038. PubMed ID: 33441781
[TBL] [Abstract][Full Text] [Related]
2. The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis.
Jeon CY; Pandol SJ; Wu B; Cook-Wiens G; Gottlieb RA; Merz CN; Goodman MT
PLoS One; 2015; 10(4):e0121783. PubMed ID: 25830309
[TBL] [Abstract][Full Text] [Related]
3. Metformin Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: A Propensity Score Analysis.
Amin S; Mhango G; Lin J; Aronson A; Wisnivesky J; Boffetta P; Lucas AL
Am J Gastroenterol; 2016 Sep; 111(9):1350-7. PubMed ID: 27430290
[TBL] [Abstract][Full Text] [Related]
4. Impact of Concurrent Medication Use on Pancreatic Cancer Survival-SEER-Medicare Analysis.
Beg MS; Gupta A; Sher D; Ali S; Khan S; Gao A; Stewart T; Ahn C; Berry J; Mortensen EM
Am J Clin Oncol; 2018 Aug; 41(8):766-771. PubMed ID: 28079594
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonate Use Does Not Impact Survival in Patients with Pancreatic Cancer: A Propensity Score Matching Analysis.
Zylberberg HM; Rustgi SD; Yang A; Aronson A; Kessel E; Amin S; Lucas AL
Gut Liver; 2021 Sep; 15(5):782-790. PubMed ID: 34158422
[TBL] [Abstract][Full Text] [Related]
6. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis.
Amin S; Baine M; Meza J; Lin C
BMC Cancer; 2020 Jun; 20(1):538. PubMed ID: 32517661
[TBL] [Abstract][Full Text] [Related]
7. Beta-Blocker Drug Use and Survival among Patients with Pancreatic Adenocarcinoma.
Udumyan R; Montgomery S; Fang F; Almroth H; Valdimarsdottir U; Ekbom A; Smedby KE; Fall K
Cancer Res; 2017 Jul; 77(13):3700-3707. PubMed ID: 28473530
[TBL] [Abstract][Full Text] [Related]
8. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
[TBL] [Abstract][Full Text] [Related]
9. The Main Bottleneck for Non-Metastatic Pancreatic Adenocarcinoma in Past Decades: A Population-Based Analysis.
Li Y; Liu W; Zhao L; Xu Y; Yan T; Yang Q; Pei Q; Güngör C
Med Sci Monit; 2020 May; 26():e921515. PubMed ID: 32358953
[TBL] [Abstract][Full Text] [Related]
10. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Impact of Cell Division Cycle Associated 2 Expression on Pancreatic Ductal Adenocarcinoma.
Wang MY; Niu ZY; Gao XG; Zhou L; Liao Q; Zhao YP
Chin Med Sci J; 2016 Sep; 31(3):149-154. PubMed ID: 27733221
[TBL] [Abstract][Full Text] [Related]
12. Marital status and survival in pancreatic cancer patients: a SEER based analysis.
Baine M; Sahak F; Lin C; Chakraborty S; Lyden E; Batra SK
PLoS One; 2011; 6(6):e21052. PubMed ID: 21698253
[TBL] [Abstract][Full Text] [Related]
13. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
[TBL] [Abstract][Full Text] [Related]
14. Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson.
Chaiteerakij R; Petersen GM; Bamlet WR; Chaffee KG; Zhen DB; Burch PA; Leof ER; Roberts LR; Oberg AL
J Clin Oncol; 2016 Jun; 34(16):1898-904. PubMed ID: 27069086
[TBL] [Abstract][Full Text] [Related]
15. Body mass index does not affect the survival of pancreatic cancer patients.
Jiang QL; Wang CF; Tian YT; Huang H; Zhang SS; Zhao DB; Ma J; Yuan W; Sun YM; Che X; Zhang JW; Chu YM; Zhang YW; Chen YT
World J Gastroenterol; 2017 Sep; 23(34):6287-6293. PubMed ID: 28974895
[TBL] [Abstract][Full Text] [Related]
16. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
17. Metformin Use and Pancreatic Cancer Survival among Non-Hispanic White and African American U.S. Veterans with Diabetes Mellitus.
Toriola AT; Luo S; Thomas TS; Drake BF; Chang SH; Sanfilippo KM; Carson KR
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):169-175. PubMed ID: 31685560
[TBL] [Abstract][Full Text] [Related]
18. Reduced mean platelet volume levels predict shorter survival in patients with resectable pancreatic ductal adenocarcinoma and type 2 diabetes.
Yin JB; Li N; Cui MM; Wang X; Wang RT
BMC Gastroenterol; 2020 May; 20(1):143. PubMed ID: 32393273
[TBL] [Abstract][Full Text] [Related]
19. Effect of prior cancer on survival outcomes for patients with pancreatic adenocarcinoma: a propensity score analysis.
He C; Zhang Y; Cai Z; Lin X
BMC Cancer; 2019 May; 19(1):509. PubMed ID: 31142278
[TBL] [Abstract][Full Text] [Related]
20. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
